International Journal of Endocrinology and Metabolism

Published by: Kowsar

Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves’ Ophthalmopathy: Good Results After Long-Term Follow-Up

Luca Nicosia 1 , 2 , * , Chiara Reverberi 1 , Linda Agolli 1 , Luca Marinelli 1 , Vitaliana De Sanctis 1 , Giuseppe Minniti 3 , 4 , Maurizio Valeriani 1 and Mattia F Osti 1
Authors Information
1 Department of Radiation Oncology, Sant’ Andrea Hospital, Sapienza University of Rome, Rome, Italy
2 Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Verona, Italy
3 Radiation Oncology Unit, UPMC Hillman Cancer Center, San Pietro Hospital, Rome, Italy
4 IRCCS Neuromed, Pozzilli (IS), Italy
Article information
  • International Journal of Endocrinology and Metabolism: January 31, 2019, 17 (1); e84427
  • Published Online: January 27, 2019
  • Article Type: Research Article
  • Received: September 20, 2018
  • Revised: January 14, 2019
  • Accepted: January 21, 2019
  • DOI: 10.5812/ijem.84427

To Cite: Nicosia L, Reverberi C, Agolli L, Marinelli L, De Sanctis V, et al. Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves’ Ophthalmopathy: Good Results After Long-Term Follow-Up, Int J Endocrinol Metab. 2019 ; 17(1):e84427. doi: 10.5812/ijem.84427.

Abstract
Copyright © 2019, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Footnotes
References
  • 1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362(8):726-38. doi: 10.1056/NEJMra0905750. [PubMed: 20181974]. [PubMed Central: PMC3902010].
  • 2. Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320-32. doi: 10.1210/jc.2010-1962. [PubMed: 21239515].
  • 3. Kouloulias V, Kouvaris J, Zygogianni A, Mosa E, Georgakopoulos J, Theodosiadis P, et al. Efficacy and toxicity of radiotherapy for Graves’ ophthalmopathy: The university of athens experience. Head Neck Oncol. 2013;5(2):12.
  • 4. Marcocci C, Marino M. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):325-37. doi: 10.1016/j.beem.2011.11.005. [PubMed: 22632369].
  • 5. Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, et al. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: Follow-up of a randomized clinical trial. J Clin Endocrinol Metab. 2012;97(1):E44-8. doi: 10.1210/jc.2011-2077. [PubMed: 22031515].
  • 6. Matthiesen C, Thompson JS, Thompson D, Farris B, Wilkes B, Ahmad S, et al. The efficacy of radiation therapy in the treatment of Graves' orbitopathy. Int J Radiat Oncol Biol Phys. 2012;82(1):117-23. doi: 10.1016/j.ijrobp.2010.08.053. [PubMed: 21030157].
  • 7. Bartalena L, Marcocci C, Tanda ML, Rocchi R, Mazzi B, Barbesino G, et al. Orbital radiotherapy for Graves' ophthalmopathy. Thyroid. 2002;12(3):245-50. doi: 10.1089/105072502753600223. [PubMed: 11952048].
  • 8. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for graves' orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857-65. doi: 10.1210/jc.2012-2758. [PubMed: 22962421].
  • 9. Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, et al. Long-term outcome of Graves' orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Invest. 2015;38(6):661-8. doi: 10.1007/s40618-015-0241-7. [PubMed: 25596664].
  • 10. Grassi P, Strianese D, Piscopo R, Pacelli R, Bonavolonta G. Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids? Ir J Med Sci. 2017;186(3):647-52. doi: 10.1007/s11845-016-1542-3. [PubMed: 28050807].
  • 11. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004;89(1):15-20. doi: 10.1210/jc.2003-030809. [PubMed: 14715820].
  • 12. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001;108(9):1523-34. doi: 10.1016/S0161-6420(01)00632-7. [PubMed: 11535445].
  • 13. Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, et al. Orbital radiation for graves ophthalmopathy: A report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(2):398-409. doi: 10.1016/j.ophtha.2007.10.028. [PubMed: 18082885].
  • 14. Prabhu RS, Liebman L, Wojno T, Hayek B, Hall WA, Crocker I. Clinical outcomes of radiotherapy as initial local therapy for Graves' ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery. Radiat Oncol. 2012;7:95. doi: 10.1186/1748-717X-7-95. [PubMed: 22713684]. [PubMed Central: PMC3485155].
  • 15. Soeters MR, van Zeijl CJ, Boelen A, Kloos R, Saeed P, Vriesendorp TM, et al. Optimal management of Graves orbitopathy: A multidisciplinary approach. Neth J Med. 2011;69(7):302-8. [PubMed: 21934174].
  • 16. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273-85. doi: 10.1530/EJE-07-0666. [PubMed: 18299459].
  • 17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341-6. doi: 10.1016/0360-3016(95)00060-C. [PubMed: 7713792].
  • 18. Menconi F, Profilo MA, Leo M, Sisti E, Altea MA, Rocchi R, et al. Spontaneous improvement of untreated mild Graves' ophthalmopathy: Rundle's curve revisited. Thyroid. 2014;24(1):60-6. doi: 10.1089/thy.2013.0240. [PubMed: 23980907]. [PubMed Central: PMC3887427].
  • 19. Wiersinga WM, Prummel MF. Graves' ophthalmopathy: A rational approach to treatment. Trends Endocrinol Metab. 2002;13(7):280-7. doi: 10.1016/S1043-2760(02)00622-7. [PubMed: 12163229].
  • 20. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011;364(20):1920-31. doi: 10.1056/NEJMoa1012985. [PubMed: 21591944].
  • 21. Minakaran N, Ezra DG. Rituximab for thyroid-associated ophthalmopathy. Cochrane Database Syst Rev. 2013;(5). CD009226. doi: 10.1002/14651858.CD009226.pub2. [PubMed: 23728689].
  • 22. Sanyal P, Bing-You RG, Braverman LE. Use of methotrexate to treat isolated Graves ophthalmopathy developing years after thyroidectomy and iodine 131 treatment of papillary thyroid cancer. Endocr Pract. 2008;14(4):422-5. doi: 10.4158/EP.14.4.422. [PubMed: 18558593].
  • 23. Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol. 2001;85(10):1220-4. doi: 10.1136/bjo.85.10.1220. [PubMed: 11567968]. [PubMed Central: PMC1723732].
  • 24. Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of graves' ophthalmopathy. Hormones (Athens). 2002;1(2):76-90. doi: 10.14310/horm.2002.1155. [PubMed: 17110359].
  • 25. Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2016;254(5):991-8. doi: 10.1007/s00417-016-3280-7. [PubMed: 26876240].
  • 26. Bartalena L. What to do for moderate-to-severe and active Graves' orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf). 2010;73(2):149-52. doi: 10.1111/j.1365-2265.2010.03783.x. [PubMed: 20148907].
  • 27. Viani GA, Boin AC, De Fendi LI, Fonseca EC, Stefano EJ, Paula JS. Radiation therapy for Graves' ophthalmopathy: Asystematic review and meta-analysis of randomized controlled trials. Arq Bras Oftalmol. 2012;75(5):324-32. doi: 10.1590/S0004-27492012000500006. [PubMed: 23471326].
  • 28. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: Systematic review and metaanalysis. J Clin Endocrinol Metab. 2009;94(8):2708-16. doi: 10.1210/jc.2009-0376. [PubMed: 19491222].
  • 29. Marquez SD, Lum BL, McDougall IR, Katkuri S, Levin PS, MacManus M, et al. Long-term results of irradiation for patients with progressive Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys. 2001;51(3):766-74. doi: 10.1016/S0360-3016(01)01699-6. [PubMed: 11697323].
  • 30. Rajendram R, Taylor PN, Wilson VJ, Harris N, Morris OC, Tomlinson M, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): A multicentre, 2 x 2 factorial, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(4):299-309. doi: 10.1016/S2213-8587(18)30021-4. [PubMed: 29396245].
  • 31. Schaefer U, Hesselmann S, Micke O, Schueller P, Bruns F, Palma C, et al. A long-term follow-up study after retro-orbital irradiation for Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys. 2002;52(1):192-7. doi: 10.1016/S0360-3016(01)01754-0. [PubMed: 11777638].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments